Abdulrahman Katib on STORM-PE Results In Favour of Thrombectomy in PE
Abdulrahman Katib, Internal Medicine and Adult Thrombosis Consultant at King Faisal Specialist Hospital and Research Center, shared on LinkedIn:
”Despite the modest sample size, STORM-PE is the first RCT showing that mechanical thrombectomy (using a computer-assisted vacuum system) combined with anticoagulation showed superior physiologic outcomes compared with anticoagulation alone in intermediate-high-risk PE.
The primary endpoint was the change in RV/LV ratio at 48 hours.
Which was segnificantly reduced in the mechanical thrombectomy (CAVT) plus anticoagulation arm.
Worth reading!”
Read the full article here.
Article: Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial
Authors: Robert A. Lookstein, Stavros V. Konstantinides, Ido Weinberg, Suhail Y. Dohad, Zachary Rosol, Grzegorz Kopeć, John M. Moriarty, Sahil A. Parikh, Andrew Holden, Richard N. Channick, Braedon McDonald, Khanjan H. Nagarsheth, Kei Yamada, Rachel P. Rosovsky for the STORM-PE Trial Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 14, 2026, 19:28Vishnu Priya Pulipati: Statins Beyond Cholesterol for Plaque Biology and Cardiovascular Risk Reduction
-
Mar 14, 2026, 19:19Yunpeng Xue: Humbled and Honored to Receive the 2025 Eberhard F. Mammen Young Investigator Award
-
Mar 14, 2026, 19:13Abhilasha Singh: A Novel Mechanism of Cardiac Aging and Disruption of The Neurovascular Network
-
Mar 14, 2026, 19:08Saleh Owimer: The Critical Rules of Safe Blood Transfusion
-
Mar 14, 2026, 19:01Omar Adwan: Correcting Lipemic Samples in CBC Using the Plasma Replacement Method
-
Mar 14, 2026, 16:28Abdul Mannan: Advancing VWF Activity Testing Beyond VWF:RCo in Clinical Laboratories
-
Mar 14, 2026, 16:26Rida Fatima: When The Body’s Most Vital Production Unit Stops Working
-
Mar 14, 2026, 16:16Martin Haluzík: Metabolic Risk Factors and Therapeutic Opportunities in Cardiovascular Disease
-
Mar 14, 2026, 16:10Raffaella Colombatti: Proud to Have Authored the New Lancet Seminar on Sickle Cell Disease